【2020.10.29】2020 ATC抗體藥物研討會
後疫情時代抗體藥物 暨 新興抗體藥品開發策略
隨著基因體學的發展，使得疾病的複雜度提升，而精準治療的觀念被重視使得標靶治療的藥品需求度成長。抗體藥品因具有高專一性，被期待用於治療未滿足之醫療需求，抗體藥品的開發成為世界新藥開發的主流之一。此外，2020年年初所爆發之COVID-19對全球經濟、社會造成重大影響，抗體藥品亦為治療藥品開發重要方向之一。
本次研討會將邀請各特色抗體藥物開發者將由醫療需求出發，觀察後疫情時代抗體藥品發展概況，及新興抗體藥品治療未滿足之醫療需求的開發策略進行分享，期能激盪與會者更多對於後疫情時代抗體藥品及新興抗體藥品之開發靈感。
日期：2020年10月29日 (星期四)上午10:30
地點：國家生技研究園區C棟國際會議廳 (南港區研究院路一段130巷99號)
活動網站：活動網站連結
報名連結：>>>點我報名
講者：
|
Time |
Activities |
Speaker |
|---|---|---|
|
10:00-10:30 |
Registration |
|
|
10:30-10:35 |
Welcome Remarks |
Chung-hsiun Wu, Ph.D. (吳忠勳理事長), Chairman of TAA |
|
10:35-10:40 |
Moderator |
Chung-hsiun Wu, Ph.D. (吳忠勳理事長), Chairman of TAA |
|
10:40-11:10 |
Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike |
David D. Ho, M.D. (何大一院士), Director, Aaron Diamond AIDS Research Center, Columbia University |
|
11:10-11:40 |
Medical requirements for COVID-19 treatments (Tentative) |
Chang-Youh Tsai, M.D., Ph.D. (蔡長祐主任), Director, Division of Allergy, Immunology and Rheumatology, Taipei Veterans General Hospital |
|
11:40-12:10 |
Using Monoclonal antibody for COVID-19 treatment — B Cell Antibody drug development platform (Tentative) |
Kuan-Ying Arthur Huang, M.D., Ph.D. (黃冠穎醫師), Associate Professor, Chang Gung Medical Foundation |
|
12:10-12:15 |
Group photo |
|
|
12:15-13:20 |
Lunch 2nd meeting of the 3rd TAA Board of Directors |
|
|
13:20-13:30 |
2nd meeting of the 3rd TAA General Assembly |
|
|
13:30-13:35 |
Moderator |
Wei-Kuang Chi, Ph.D. (紀威光副執行長), Vice President, R&D, Development Center for Biotechology |
|
13:35-14:05 |
Diagnostics of COVID-19 and invention of therapeutics mAb—monoclonal antibody (Tentative) |
Han-Chung Wu , Ph.D. (吳漢忠主任), Director, BioTReC |
|
14:05-14:35 |
CDMO supporting COVID-19 antibody drug development service (Tentative) |
Lee-Cheng Liu, Ph.D. (劉理成總經理), President & CEO, EirGenix Inc. |
|
14:35-14:55 |
Break |
|
|
14:55-15:00 |
Moderator |
Shih-Chong Tsai, Ph.D. (蔡士昌所長), Executive Director, Institute of Biologics, Development Center for Biotechnology |
|
15:00-15:30 |
Current development of Antibody drug conjugates (ADC) (Tentative) |
Shih-Hsien Chuang, Ph.D. (莊士賢副所長), Deputy Director, Institute of Pharmaceutics, Development Center for Biotechnology |
|
15:30-16:00 |
Proteomic profiling of antibody-drug conjugate biomarker panel for rational drug design |
Sheeno Thyparambil, Ph.D., Senior Director R&D, mProbe Inc. |
|
16:00-16:05 |
Closing Remarks |
Chung-hsiun Wu, Ph.D. (吳忠勳理事長), Chairman of TAA |
- ※ 論壇全程以英文進行，主辦單位保留活動變更權力